# Targeting inflammatory factors for chemoprevention and cancer interception to tackle malignant mesothelioma

## TL;DR

This paper reviews strategies to prevent or intercept mesothelioma, a deadly cancer caused by asbestos exposure, by targeting inflammatory factors.

## Contribution

The paper provides a comprehensive review of chemoprevention and cancer interception approaches for asbestos-induced mesothelioma.

## Key findings

- Preclinical models and inflammatory targets for mesothelioma prevention are discussed.
- Phytochemicals and synthetic agents show potential in early studies.
- Past and future clinical trials for chemoprevention in asbestos-exposed populations are analyzed.

## Abstract

Mesothelioma is an incurable cancer of the mesothelial lining often caused by exposure to asbestos. Asbestos-induced inflammation is a significant contributing factor in the development of mesothelioma, and genetic factors also play a role in the susceptibility to this rapidly progressive and treatment-resistant malignancy. Consequently, novel approaches are urgently needed to treat mesothelioma and prevent or reduce the overall incidence of this fatal disease. In this research perspective, we review the current state of chemoprevention and cancer interception progress in asbestos-induced mesothelioma. We discuss the different preclinical mouse models used for these investigations and the inflammatory factors that may be potential targets for mesothelioma prevention. Preliminary studies with naturally occurring phytochemicals and synthetic agents are reviewed. Results of previous clinical chemoprevention trials in populations exposed to asbestos and considerations regarding future trials are also presented.